A faster route to eliminating parasitic infection endemic to Africa (IMAGE)
Caption
Philip Budge, MD, PhD (center), an associate professor in the Division of Infectious Diseases at WashU Medicine, speaks with collaborators Benjamin Koudou of the Centre Suisse de Recherches Scientifiques (CSRS) in Côte d'Ivoire (left) and Catherine Bjerum, MD, of Case Western Reserve University. Their recent clinical trial finds the anti-parasitic drug moxidectin – currently approved to treat river blindness, another tropical disease caused by parasitic worms – is also more effective for lymphatic filariasis than the current gold standard, ivermectin.
Credit
Matt Miller
Usage Restrictions
Restrictions for original art: This image is to be used in accordance with the mission, policies and guidelines of Washington University in St. Louis. Visit https://wustl.edu/about/compliance-policies/media-policies/multimedia-use/ for more information.
License
Original content